The $29.5 Billion Molecule
One drug accounts for 46% of everything Merck sells. Not a category. Not a therapeutic area. A single molecule — pembrolizumab, marketed as Keytruda — generated $29.5 billion in worldwide sales in 2024, making it the bestselling pharmaceutical product on the planet for the second consecutive year. To put that in context: Keytruda alone produces more revenue than the entirety of Bristol-Myers Squibb's oncology franchise, more than Moderna's total sales, more than the
GDP of Iceland. And yet this number, staggering as it is, encodes Merck's most dangerous strategic problem. Keytruda's core composition-of-matter patent expires in 2028. The subcutaneous formulation — approved by the FDA in September 2025 — extends protection somewhat, but the cliff is visible, approaching at speed, and the market knows it. In the eighteen months between January 2024 and mid-2025, Merck's share price declined roughly 35% from its highs, even as the company posted record revenue. The market was not punishing Merck for what it earned. It was punishing Merck for what it might lose.
This is the central paradox of one of the world's oldest pharmaceutical companies: Merck has constructed, over 130 years, one of the most scientifically productive drug discovery machines in human history — the company that gave the world statins, developed the first measles vaccine, eradicated river blindness in sub-Saharan Africa, and pioneered checkpoint inhibitor immunotherapy. And all of that history, all of that capability, has been funneled into a revenue profile so concentrated that a single patent expiration could hollow out nearly half the enterprise. The story of Merck is, in one reading, the story of scientific genius compounding over decades. In another, it is a case study in the pathology of blockbuster dependence — and the frantic, brilliant, sometimes desperate maneuvers pharmaceutical companies execute when the clock starts ticking.
By the Numbers
Merck in 2024
$64.2BFull-year worldwide sales
$29.5BKeytruda sales (46% of total revenue)
$8.6BGardasil/Gardasil 9 sales
$5.9BAnimal Health segment sales
~74,000Employees worldwide
$7.65Non-GAAP EPS (FY2024)
$419MWinrevair launch-year sales
20Potential blockbuster drugs in pipeline
An Angel in Darmstadt
The pharmaceutical industry's most confusing corporate genealogy begins in 1668, when a German pharmacist named Friedrich Jacob Merck acquired a small apothecary called the Angel Pharmacy in Darmstadt, Germany. For a century and a half, the Merck family operated as provincial chemists. Then Heinrich Emanuel Merck, taking over in 1816, did something that would become the template for the modern pharmaceutical industry: he applied scientific methods to drug production, isolating alkaloids — morphine, codeine, cocaine — in standardized, reproducible forms. Chemistry, not alchemy. By the end of the nineteenth century, the Merck family business had expanded across the Atlantic.
In 1891, Merck established a subsidiary in New York — Merck & Co. — to capitalize on the booming American market. For two decades, the German parent and American subsidiary operated as a single organism. Then came the rupture. When the United States entered World War I in 1917, the Trading with the Enemy Act classified all German-owned assets as enemy property. The U.S. government seized Merck & Co. and auctioned it off. George Merck, an American citizen and grandson of the founder, purchased the confiscated entity and rebuilt it as an independent American corporation. The original German company — Merck KGaA — survived in Darmstadt. The two Mercks have been legally separate ever since, connected by name and origin but divided by war. Under a complex and frequently litigated agreement, the American company uses "Merck" in the United States and Canada and operates as "MSD" (Merck Sharp & Dohme) everywhere else, while the German company uses "Merck" globally except in North America, where it operates as "EMD Serono."
This corporate schizophrenia — the same name, two unrelated companies, geographically partitioned branding — is more than a curiosity. It is a permanent tax on Merck's global identity, a legacy of the violent twentieth century embedded in the company's letterhead.
Merck's strategic arc across 130+ years
1668Friedrich Jacob Merck acquires Angel Pharmacy in Darmstadt, Germany.
1891Merck & Co. established in New York as a U.S. subsidiary of the German parent.
1917U.S. government seizes Merck & Co. under Trading with the Enemy Act; George Merck repurchases and rebuilds it.
1953Merck & Co. merges with Sharp & Dohme, creating MSD and expanding into vaccines.
1985Roy Vagelos becomes CEO; launches golden era of R&D-driven blockbusters.
1987Merck donates Mectizan (ivermectin) to eradicate river blindness — forever, for free.
2004Voluntary withdrawal of Vioxx devastates Merck financially and reputationally.
The Vagelos Doctrine
If you want to understand why Merck's culture operates differently from most large pharmaceutical companies — and why that difference is both its greatest asset and the source of recurring strategic tension — you need to understand P. Roy Vagelos, the biochemist who ran Merck from 1985 to 1994 and whose intellectual fingerprints remain on the institution three decades later.
Vagelos was the son of Greek immigrants who ran a small restaurant in Rahway, New Jersey — the same city where Merck's U.S. headquarters would eventually sit. He trained as a physician at Columbia, then pivoted to biochemistry research at the National Institutes of Health, where he spent over a decade as head of the biochemistry section. He wasn't a dealmaker or a salesman. He was a bench scientist who happened to develop the organizational instincts of a chief executive. When he joined Merck Research Laboratories in 1975, the company was respected but unfocused, producing solid but unremarkable products. Vagelos made a bet that would define the next era: he restructured the entire R&D operation around hypothesis-driven science, recruiting academic researchers, investing heavily in basic biology, and insisting that Merck's competitive advantage would come from understanding disease mechanisms better than anyone else.
The results were extraordinary. Under Vagelos, Merck developed lovastatin (Mevacor), the first commercially available statin, which opened a therapeutic category that would eventually treat hundreds of millions of patients worldwide. Merck introduced enalapril (Vasotec), a blockbuster ACE inhibitor. The company developed the first recombinant hepatitis B vaccine. During Vagelos's tenure, Merck was named Fortune's "Most Admired Company in America" seven consecutive years — a record that stands unchallenged.
But the decision that most clearly reveals Merck's institutional DNA came in 1987, when Vagelos confronted a problem with no commercial solution. Merck scientists had developed ivermectin for veterinary use (it was spectacularly effective against parasites in livestock). Research showed that a human formulation — eventually branded Mectizan — could cure onchocerciasis, or river blindness, a disease that had blinded millions in sub-Saharan Africa and Latin America. The problem: the people who needed the drug could not pay for it, and no government or international body was willing to fund distribution.
We try never to forget that medicine is for the people. It is not for the profits. The profits follow, and if we have remembered that, they have never failed to appear.
Vagelos decided Merck would manufacture and donate Mectizan to anyone who needed it, for as long as necessary. "For as long as necessary" turned out to mean forever — the Mectizan Donation Program, launched in 1987, continues today and has distributed over four billion treatments. It is, by any measure, one of the most consequential corporate philanthropic acts in history. It also established something that would reverberate through Merck's culture for decades: the belief that the company's legitimacy rested not merely on financial performance but on the moral authority of its science. This was not just sentiment. It became a recruitment tool, a retention mechanism, and an internal compass that guided decisions about pipeline investment, pricing, and access in ways that often baffled Wall Street.
The Vagelos doctrine — science first, profits follow — is the closest thing Merck has to a founding creed. It attracts a certain kind of scientist, a certain kind of leader. It also creates a structural vulnerability: when the science produces a single drug so successful that it dominates the portfolio, the creed offers no easy mechanism for diversification. You cannot will the next breakthrough into existence. You can only fund the search.
The Vioxx Reckoning
Every great pharmaceutical company carries a scar. For Merck, it is Vioxx.
Rofecoxib, marketed as Vioxx, was a COX-2 selective anti-inflammatory drug approved by the FDA in 1999 for the treatment of osteoarthritis, acute pain, and menstrual symptoms. It was a genuine blockbuster — peak annual sales approached $2.5 billion. It was also, according to mounting evidence, associated with an elevated risk of heart attacks and strokes. On September 30, 2004, Merck voluntarily withdrew Vioxx from the global market after a clinical trial showed that patients taking the drug for more than eighteen months faced roughly double the risk of cardiovascular events compared to placebo.
The withdrawal was devastating. Merck's market capitalization dropped by approximately $27 billion in a single day. Thousands of lawsuits followed — at one point, the company faced an estimated 50,000 individual claims and dozens of class actions. The legal and settlement costs would eventually total nearly $5 billion. Careers ended. Reputations were shattered. Congressional hearings dissected Merck's internal communications, with critics arguing the company had known about cardiovascular risks far earlier than it acknowledged. Merck disputed this characterization, maintaining that it had acted responsibly given the evolving scientific evidence and that the voluntary withdrawal itself demonstrated good faith.
What Vioxx did to Merck's culture, though, may have mattered more than what it did to the balance sheet. The company had built its identity on scientific integrity and the moral authority of its research. Vioxx threw that identity into crisis. Internal morale suffered. Recruitment of top scientists became harder. The company entered a period of strategic drift — cutting R&D, losing its pipeline edge, watching competitors like Pfizer and Roche surge ahead in oncology and biologics.
The Vioxx era illustrates a dynamic that recurs throughout pharmaceutical history: the company that is most committed to its scientific identity is most vulnerable when that identity is challenged. The fall hit harder precisely because Merck believed its own story. It would take nearly a decade — and a new class of leaders — to rebuild.
The Lawyer Who Rebuilt the Lab
Kenneth C. Frazier was not the obvious choice to lead Merck. He was not a scientist. He was not a salesman. He was a trial lawyer — the son of a janitor, raised in inner-city Philadelphia, one generation removed from sharecroppers in the rural South. Frazier had joined Merck's legal department in 1992 and made his name defending the company during the Vioxx litigation, where he personally tried one of the bellwether cases and won a jury verdict that helped shift the trajectory of the entire litigation portfolio. His courtroom performance was the kind of thing that gets remembered in corporate corridors for decades — precise, empathetic, devastatingly prepared.
When Frazier became CEO in 2011, Merck was a diminished version of itself. Revenue had been essentially flat for years. The pipeline was thin. The company had completed its acquisition of Schering-Plough in 2009 — a $41 billion deal that added scale but also complexity and integration headaches. Frazier's mandate was to rebuild the research engine while stabilizing operations.
I'm the son of a man who was born in the rural South and had a third-grade education. He grew up in the shadow of a real institution — not slavery anymore, but Jim Crow. He used to say to me, 'What you do for work is not who you are. Who you are is how you treat people.'
The most consequential decision of Frazier's tenure — arguably the most consequential decision in Merck's modern history — was one that looked unremarkable at the time. In 2011, Merck's scientists were working on a monoclonal antibody called lambrolizumab, a PD-1 checkpoint inhibitor designed to release the immune system's brakes on cancer cells. Checkpoint inhibition was an emerging but unproven therapeutic concept. Bristol-Myers Squibb was ahead in the race, with nivolumab (Opdivo) progressing through clinical trials. Other pharmaceutical companies viewed PD-1 inhibitors with skepticism — the mechanism was theoretically elegant but clinically uncertain. Merck could have deprioritized the program.
Frazier didn't. Under his leadership, Merck accelerated the clinical development of what would become pembrolizumab — Keytruda. The company pursued an aggressive regulatory strategy, securing breakthrough therapy designation from the FDA and pursuing an initial indication in advanced melanoma. On September 4, 2014, the FDA approved Keytruda for the treatment of advanced or unresectable melanoma in patients who had not responded to other drugs. It was the first PD-1 inhibitor to reach the U.S. market — beating Opdivo by months.
The sequence matters. In the checkpoint inhibitor race, being first meant capturing physician mindshare, building clinical data, and establishing commercial infrastructure before the competition. Merck's clinical teams then executed a label-expansion strategy of breathtaking ambition, running hundreds of trials across dozens of tumor types. Keytruda accumulated approvals in non-small cell lung cancer, head and neck cancer, bladder cancer, renal cell carcinoma, Hodgkin lymphoma, gastric cancer, cervical cancer, hepatocellular carcinoma, and many more — eventually securing more than 40 approved indications globally, the broadest label of any oncology drug in history.
Frazier also made a decision about corporate conscience that would define his public profile. In August 2017, following the deadly white supremacist rally in Charlottesville, Virginia, Frazier resigned from President Trump's American Manufacturing Council — the first CEO to do so — issuing a statement against "hatred, bigotry, and group supremacy." It was a gesture that carried real risk for a company whose business depends on government regulatory approvals, Medicare pricing negotiations, and federal research funding. Several other CEOs followed Frazier's lead, and the council eventually disbanded. But Frazier was first, and the act cemented his reputation as the rare Fortune 500 CEO willing to stake corporate capital on moral principle.
When Frazier stepped down as CEO in 2021, handing the role to Robert M. Davis, he left behind a company utterly transformed — and utterly dependent on a single product.
The Concentration Trap
By 2024, Keytruda's dominance of Merck's revenue profile had reached a level that industry analysts described, with varying degrees of alarm, as unprecedented for a major pharmaceutical company. At $29.5 billion in annual sales — growing 18% year over year, or 22% excluding foreign exchange effects — Keytruda represented approximately 46% of Merck's $64.2 billion in total revenue. No other drug in the company's portfolio came close. Gardasil/Gardasil 9, the HPV vaccine franchise that had been Merck's second pillar, generated $8.6 billion — but that number was declining, down 3% from the prior year, with the China market in particular creating acute headaches as elevated inventory levels forced Merck to temporarily pause shipments, potentially through mid-2025.
The financial paradox was stark. Keytruda was growing faster than any other major oncology drug, expanding into earlier lines of therapy, into adjuvant settings, into combinations with Merck's own pipeline assets and those of partners. The molecule was not merely surviving — it was accelerating. Yet the market treated this growth as a countdown, because the composition-of-matter patent expires in 2028. After that date, biosimilar competitors will be free to enter the market. The precise speed and magnitude of revenue erosion is uncertain — biosimilar competition typically plays out more slowly than small-molecule generic competition — but Wall Street consensus models projected significant revenue losses in the years following patent expiration.
This is the fundamental strategic challenge that CEO Rob Davis inherited and that has consumed the company's capital allocation since he took the helm.
Davis came to Merck from Baxter International, where he had served as CFO. He is not a scientist, not a lawyer — he is a finance executive, a capital allocator, a systems thinker. His temperament is less dramatic than Frazier's, his public profile lower, his instincts more operational. In the context of Merck's strategic moment, this background may be precisely what's needed. The question facing Merck is not "Can we do great science?" — that capability is embedded in the institution's DNA. The question is "Can we replace $29.5 billion in revenue before the patent cliff arrives?" That is an allocation problem, a portfolio construction problem, a timing problem. It is, fundamentally, a CFO's problem.
We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including for Keytruda, which continues to benefit more patients with cancer globally, the successful launch of Winrevair and strong performance of our Animal Health business. Our business remains well positioned thanks to the dedication of our talented global team, and I am more confident than ever in our long-term growth potential.
The Subcutaneous Gambit
The first line of defense against the Keytruda cliff is Keytruda itself — or, more precisely, a reformulated version of it. In September 2025, the FDA approved a subcutaneous injection formulation of pembrolizumab combined with berahyaluronidase alfa. The existing intravenous infusion of Keytruda requires patients to sit in a clinical setting for approximately 30 minutes every three to six weeks. The subcutaneous version can be administered in roughly five minutes, dramatically reducing the time burden on patients and the operational cost for healthcare systems.
This is not merely a convenience upgrade. It is a patent strategy. The subcutaneous formulation carries its own intellectual property protections that extend beyond the 2028 composition-of-matter expiration. While the precise years of exclusivity are subject to legal interpretation and potential challenge, the reformulation is designed to give Merck a differentiated product that biosimilar manufacturers cannot replicate simply by copying the original molecule. If Merck can migrate a substantial portion of Keytruda patients to the subcutaneous formulation before 2028 — and if physicians and payers accept the reformulated product as the standard of care — the revenue erosion from biosimilar entry could be significantly less severe than current models project.
It is, in pharmaceutical terms, the oldest trick in the book: lifecycle management, the art of extending a franchise through reformulation, new indications, and combination therapies. But the scale at which Merck must execute this maneuver is without precedent. There has never been a $29.5 billion drug facing a patent cliff, because there has never been a $29.5 billion drug.
Twenty Blockbusters
The second line of defense is the pipeline. On the February 2025 earnings call, Merck's leadership touted a portfolio of 20 potential new blockbuster drugs — defined as products with projected peak annual sales exceeding $1 billion each — that the company estimated could generate over $50 billion in cumulative future revenue. The number was intended to calm investor nerves about the post-Keytruda era.
The most tangible evidence of pipeline productivity in 2024 was Winrevair (sotatercept), a treatment for pulmonary arterial hypertension that Merck acquired through its $11.5 billion purchase of Acceleron Pharma in 2021. Winrevair generated $419 million in sales in its first partial year on the market — a launch trajectory that, if sustained, could place it among the most successful specialty drug launches in industry history. The drug represents a fundamentally new mechanism of action for PAH, and Merck is expanding clinical trials into broader cardiovascular indications.
Beyond Winrevair, Merck's pipeline spans oncology (where the company is exploring next-generation immunotherapies, bispecific antibodies, and antibody-drug conjugates), cardiovascular and metabolic disease, infectious disease, and — in a revealing late entry — the GLP-1 obesity and diabetes space. In December 2024, Merck signed a licensing agreement with Hansoh Pharmaceutical for an investigational oral GLP-1 receptor agonist, designated MK-4082. The deal was reportedly worth up to nearly $2 billion in milestones. The GLP-1 market, dominated by Eli Lilly and Novo Nordisk, represents one of the largest revenue opportunities in pharmaceutical history — potentially exceeding $100 billion annually by the end of the decade. Merck's entry is late, differentiated only by the oral formulation (most GLP-1 drugs are injectable), and far from guaranteed to succeed. But the sheer size of the opportunity makes it a rational bet.
Merck also licensed MK-2010, an investigational anti-PD-1/VEGF bispecific antibody, from LaNova Medicines — a deal that reflects the company's strategy of extending its immuno-oncology franchise beyond the PD-1 monotherapy paradigm. And the company is advancing clesrovimab, a long-acting monoclonal antibody designed to protect infants from RSV disease, with the FDA accepting a Biologics License Application in late 2024.
The portfolio is real. The question is whether it is real enough, fast enough.
The Animal in the Room
One of the most underappreciated assets in Merck's portfolio sits in a division that receives a fraction of the analytical attention devoted to Keytruda: Animal Health. In 2024, Merck's Animal Health segment generated $5.9 billion in revenue, growing 4% year over year (8% excluding foreign exchange). This makes Merck one of the two largest animal health companies in the world, alongside Zoetis — the Pfizer spinoff that has become a Wall Street darling.
Animal Health is a remarkably stable business with different risk characteristics than human pharmaceuticals. Patent cliffs are less severe — veterinary products face less aggressive generic competition, and the customer base (farmers, veterinarians, pet owners) exhibits different purchasing dynamics. The segment covers livestock products (poultry vaccines, cattle parasiticides), companion animal products (flea and tick preventatives, pain management), and aquaculture — a growing category following Merck's recent acquisition of an aquaculture portfolio.
In any other pharmaceutical company, a $5.9 billion animal health business would be a crown jewel. At Merck, it is overshadowed by the human pharmaceutical franchise to such a degree that investors periodically call for its separation or spin-off, arguing that it would be valued more appropriately as a standalone entity. Merck's management has consistently resisted these calls, arguing that the diversification benefit — and the shared R&D capabilities in biologics and manufacturing — justify the integrated structure.
The Animal Health debate is, in miniature, the strategic debate that defines Merck: Is the company better as a focused human pharmaceutical business, concentrating all capital on the next oncology breakthrough? Or is the diversification — the steady cash flow from livestock vaccines and pet medicines — a form of insurance against the inherent volatility of the drug development lottery?
The Gardasil Complication
For years, Gardasil — Merck's quadrivalent and later nonavalent HPV vaccine — was the second pillar of the company's revenue story. The vaccine, which protects against the strains of human papillomavirus responsible for cervical cancer, throat cancer, and other malignancies, was a triumph of both science and public health. Merck essentially created the market, overcoming significant political and cultural resistance (vaccinating adolescents against a sexually transmitted virus was, to put it mildly, controversial) to build a global franchise.
Gardasil and Gardasil 9 generated $8.6 billion in 2024 — a large number by any standard, but one that masked a troubling trajectory. Sales declined 3% year over year. The problem was concentrated in China, which had become the largest market for Gardasil outside the United States. Elevated channel inventory, weakening demand in a post-COVID environment, and emerging domestic competition from Chinese vaccine manufacturers combined to create a slowdown that Merck's management described with careful understatement. The company paused shipments to China and withdrew its earlier $11 billion sales target for the franchise.
The Gardasil situation illustrates a dynamic that recurs across Merck's portfolio: the tension between first-mover advantage and the inevitability of competitive catch-up. Merck was first with HPV vaccination. It built the market. It captured enormous value. But it could not hold the market permanently — not against local competitors with lower manufacturing costs, not against governments seeking to diversify their vaccine supply chains, not against the natural maturation of a vaccination program that, as penetration increases, exhausts its addressable population.
The Institutional Memory of Science
What distinguishes Merck from most large pharmaceutical companies is not any single product or executive but something harder to quantify: an institutional commitment to science-led drug discovery that has persisted across leadership transitions, strategic crises, and market cycles for nearly a century. The company's R&D spending in 2024 was approximately $30.5 billion on a GAAP basis (which includes significant charges related to business development transactions and acquired in-process research), or roughly $16.4 billion excluding those charges. Either way, the commitment is enormous.
More importantly, the kind of science Merck pursues has historically differed from the industry norm. Where many pharmaceutical companies have shifted toward "fast-follower" strategies — waiting for competitors to validate a mechanism of action and then developing a similar molecule — Merck has repeatedly pursued first-in-class approaches that carry higher scientific risk but offer greater commercial upside and competitive defensibility. Keytruda was not a me-too PD-1 inhibitor. Mectizan was not a minor iteration. Winrevair represents a genuinely novel mechanism for PAH.
This institutional bias toward scientific risk is self-reinforcing. It attracts researchers who want to work on hard problems. It creates a culture where breakthrough discoveries are celebrated in ways that cascade through hiring, retention, and internal mythology. It produces, occasionally, drugs so differentiated that they capture entire therapeutic categories. And it produces, inevitably, periods of pipeline drought when the hard problems prove harder than expected.
The company has been recognized repeatedly for its workplace culture — appearing on Fortune's "100 Best Companies to Work For" list multiple times — and the employee testimonials are striking in their specificity. Workers describe mentorship programs, flexibility for caregivers, and a genuine sense of purpose connected to patient outcomes. This is not incidental to the business model. In an industry where the median cost of bringing a single drug to market exceeds $1 billion and the failure rate exceeds 90%, the ability to attract and retain elite scientific talent is a structural competitive advantage.
We believe that serving social good and securing long-term business success are deeply interdependent.
The NotPetya Scar and Other Unseen Risks
On June 27, 2017, a cyberattack attributed to Russian military intelligence struck Merck's global operations. The NotPetya malware — disguised as ransomware but actually designed for destruction — spread through a Ukrainian tax software update and cascaded across Merck's worldwide network. Manufacturing operations were disrupted for weeks. The company estimated the attack cost approximately $870 million in direct damages — a figure that, after a protracted legal battle with insurers, resulted in a landmark $1.4 billion settlement. The dispute centered on whether the cyberattack constituted an "act of war" excluded from standard commercial insurance policies.
NotPetya is worth dwelling on not because it was unique to Merck but because it exposed a vulnerability that the pharmaceutical industry shares with all complex global manufacturers: the fragility of interconnected digital systems. Merck has since invested heavily in cybersecurity — the company now describes its approach as a comprehensive overhaul — but the episode illustrates that existential risk in the pharmaceutical industry extends beyond patent cliffs and pipeline failures into domains that no amount of R&D spending can address.
The Clock and the Catalog
Robert Davis's strategic blueprint for Merck, as articulated through earnings calls and investor presentations in 2024 and 2025, can be summarized as a portfolio construction problem executed under extreme time pressure. The company must accomplish several things simultaneously:
Extend Keytruda's commercial life through subcutaneous reformulation, new indications, and combination therapies. Accelerate the launch and market penetration of Winrevair, targeting peak sales that some analysts estimate could exceed $5 billion annually. Advance the twenty potential blockbusters through clinical trials, regulatory approvals, and commercial launch. Execute business development — licensing deals, acquisitions, partnerships — to augment the pipeline where internal R&D cannot move fast enough. Manage the Gardasil franchise through its China disruption. Sustain the Animal Health business as a diversifying cash flow engine.
The 2025 financial outlook Merck provided in February projected worldwide sales between $64.1 billion and $65.6 billion, with non-GAAP EPS between $8.88 and $9.03. This implied modest top-line growth — essentially flat at the midpoint — as Keytruda's continued expansion was offset by Gardasil headwinds and the natural maturation of other products. The company also anticipated roughly $200 million in costs from tariff impacts, a reminder that pharmaceutical companies, for all their intellectual property moats, are not immune to the brute economics of global trade policy.
The market's verdict, reflected in the stock's decline from 2024 highs, was that Merck's execution plan was plausible but not yet proven. The pipeline assets are real but early. The Keytruda lifecycle extension is strategically sound but legally and commercially uncertain. The business development deals are promising but carry the execution risk inherent in any licensing arrangement. And the clock — 2028, when the core Keytruda patent expires — does not pause for clinical trials.
What George Merck Knew
George W. Merck — the grandson of the founder, the man who repurchased the seized company after World War I and led it through its transformation into a major American pharmaceutical enterprise — gave a speech in 1950 that is still quoted in Merck's corporate communications, still invoked by its leaders, still printed in its annual reports. The words are so embedded in the company's mythology that they function less as a statement of philosophy than as a kind of institutional catechism.
We try never to forget that medicine is for the people. It is not for the profits. The profits follow, and if we have remembered that, they have never failed to appear.
It is easy to be cynical about this kind of rhetoric — particularly when the company invoking it faces $29.5 billion in patent-protected revenue, prices its cancer immunotherapy at six figures per course of treatment, and operates in an industry where access remains catastrophically unequal across the globe. The cynicism is not entirely wrong. But it is not entirely right, either. The Mectizan program is real. The company's pricing access programs are, by industry standards, substantial. The culture that these words create — the scientists who take pay cuts to work at Merck rather than at hedge funds, the executives who frame decisions in terms of patient impact rather than quarterly earnings — is real and measurable in the quality of the pipeline, the caliber of the talent, and the longevity of the franchise.
The tension between the creed and the commercial reality is not a flaw in Merck's story. It is Merck's story. It is the tension that produces both the scientific ambition that leads to breakthrough drugs and the concentration risk that accompanies blockbuster dependence. A company that believed only in profits would diversify into contract manufacturing, financial services, anything to smooth the revenue curve. A company that believed only in the science would run itself into insolvency pursuing elegant molecules with no commercial application. Merck lives in the space between — sometimes uncomfortably, sometimes brilliantly.
In Rahway, New Jersey, in the laboratories where chemists once isolated lovastatin and immunologists first tested pembrolizumab in human subjects, a new generation of researchers is running trials on bispecific antibodies, oral GLP-1 agonists, personalized cancer vaccines, and RSV monoclonal antibodies. The clock reads 2028. The catalog reads twenty potential blockbusters. And on the wall somewhere, almost certainly, George Merck's words about medicine and profits — the ones that have never quite come true and never quite failed to appear.
